NEJM: Hydroxychloroquine does not reduce the risk of infection in close contacts with new coronary pneumonia

Recently, researchers examined the effects of hydroxychloroquine on the prevention of symptomatic infections after SARS-CoV-2 exposurestudy in the United States and Canada was conducted as a randomized, double-blind, placebo-controlled trial to test the effectiveness of hydroxychloroquine as a post-exposure preventive measureThe researchers recruited adult volunteers who were exposed to the home or professional environment of the confirmed patient, less than 6 feet from the infected person, exposed for more than 10 minutes, and did not wear a mask or goggles at the time of contact (high risk of exposure), or weara a mask but not goggles (medium risk exposure)Randomly take placebo or hydroxychloroquine (800 mg once) within 4 days of exposure, followed by 600 mg within 6 to 8 hours, and 600 mg daily for 4 daysThe main result of the study was a laboratory-confirmed Covid-19 infection within 14 days821 asymptomatic participantsOverall, 87.6 percent of the participants reported high-risk exposure to Covid-19 patientsThere was no significant difference in the incidence of new coronary pneumonia in the hydroxychloroquine treatment group (49 out of 414 cases) and the placebo group (58 out of 407 cases , 14.3%); Side effects of hydroxychloroquine were more common (40.1% vs 16.8%), but no serious adverse reactions were reportedstudy concluded that the use of hydroxychloroquine within 4 days of exposure to close contacts of new coronary pneumonia did not reduce their risk of infection